cancidas caspofungin acetate for injection 70mg per vial

Description

Indication & Scope

Caspofungin Acetate irreversibly inhibits fungal β-(1,3)-D-glucan synthase to block synthesis of fungal cell wall component glucan, causing fungal cell rupture and death. Human cells lack this target enzyme, so the drug has minimal renal toxicity compared with polyene antifungals.

Mechanism
Echinocandin cell wall-targeted antifungal
Drug class
Injectable systemic anti-infective / Deep mycosis therapeutic lyophilized powder
Clinical use
First-line echinocandin antifungal targeting fungal cell wall, low nephrotoxicity, fewer infusion reactions, suitable for neutropenia, hematological malignancy and immunocompromised patients with invasive candidiasis or refractory invasive aspergillosis.

Specification

Generic Name	Caspofungin Acetate for Injection
Brand Name	Cancidas®
Ingredient	Caspofungin Acetate
Dosage Form	Injection
Package	70mg/vial
Conditions Treated	Empirical antifungal therapy for febrile neutropenia; treat candidemia, abdominal/pleural Candida infections and esophageal candidiasis; salvage therapy for invasive aspergillosis refractory or intolerant to other antifungals.
Taboos	Patients with hypersensitivity to caspofungin acetate or any excipients of the preparation are forbidden.
Place of origin	France
Priscription Type	Prescription Drug
Storage Conditions	Sealed, store below 30°C, protected from light
Manufacturer	Fareva Mirabel
Registration Authority	National Medical Products Administration (NMPA)
Approval number	HJ20171219
Approval Date	July 29, 2022
Shelf Life	36 months

How to use ?

Recommended Dose: Intravenous slow infusion only, 60-minute infusion duration; intravenous bolus injection is forbidden.

Time: Loading dose: 70mg once on Day 1; Maintenance dose: 50mg once daily afterwards; No loading dose required for esophageal candidiasis.

Instructions for use: Adjust daily maintenance dose to 70mg when combined with CYP450 inducers. Monitor liver function, serum creatinine and serum electrolytes regularly throughout treatment.

Interaction: CYP450 enzyme inducers (rifampicin, dexamethasone, phenytoin, carbamazepine) accelerate drug clearance, maintenance dose shall be adjusted to 70mg daily; compatible only with normal saline, dextrose-containing diluents are prohibited; do not mix with other intravenous medicines.

Side effects: Fever, headache, nausea, diarrhea, elevated liver transaminase, hypokalemia, rash.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support